News

Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.

Hilleman Laboratories’ preclinical trial report on Hib vaccine offers hope to millions of children

Date: 24/06/2015

Hilleman Laboratories’ preclinical trial report on Hib vaccine offers hope to millions of children

Global vaccine research and development organisation, Hilleman Laboratories, today announced the publication of an original scientific report in the journal Vaccine based on the success of a preclinical trial conducted for Haemophilus influenzae type b (Hib) vaccine.

View All